-
公开(公告)号：US20190162737A1
公开(公告)日：2019-05-30
申请号：US16264779
申请日：2019-02-01
Inventor： Johann Karl , Peter Kastner , Roberto Latini , Serge Masson , Ursula-Henrike Wienhues-Thelen , Andre Ziegler , Manuel Dietrich , Ulrich Schotten , Vinzent Rolny
IPC: G01N33/68
Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of ESM-1 in a sample from the subject, and comparing the amount of ESM-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure and/or at least one structural or functional abnormality of the heart associated with heart failure.
-
公开(公告)号：US20210156875A1
公开(公告)日：2021-05-27
申请号：US17161998
申请日：2021-01-29
Applicant: Roche Diagnostics Operations, Inc. , Universitaet Maastricht , Academisch Ziekenhuis Maastricht
Inventor： Johann Karl , Peter Kastner , Roberto Latini , Vinzent Rolny , Ursula-Henrike Wienhues-Thelen , Andre Ziegler , Manuel Dietrich , Jennifer Meessen , Ulrich Schotten
IPC: G01N33/68
Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of DKK3 in a sample from the subject, and comparing the amount of DKK3 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure and/or at least one structural or functional abnormality of the heart associated with heart failure.
-
公开(公告)号：US20180196067A1
公开(公告)日：2018-07-12
申请号：US15911699
申请日：2018-03-05
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Dirk Block , Roberto Latini , Serge Masson , Ursula-Henrike Wienhues-Thelen , Christian Zaugg
CPC classification number: G01N33/6887 , A61B5/055 , A61B8/0883 , G01N33/82 , G01N2333/4703 , G01N2333/4706 , G01N2333/4712 , G01N2333/50 , G01N2333/78 , G01N2800/32 , G01N2800/329 , G01N2800/50
Abstract: The present invention relates to a method for assessing whether a subject shall be subjected to an imaging based diagnostic assessment. The method is based on the determination of the amount(s) of a cardiac Troponin and/or Fibroblast Growth Factor 23 (FGF-23) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). The present invention also relates to a system for performing an assessment whether a subject shall be subjected to an imaging based diagnostic assessment and to reagents and kits used in performing the methods disclosed herein. Moreover, the present invention is directed to a method for predicting the risk of mortality and/or of a cardiovascular event. Also encompassed is a method for diagnosing an early stage of LVH in a subject having a preserved left ventricular ejection.
-
公开(公告)号：US20230095167A1
公开(公告)日：2023-03-30
申请号：US17801469
申请日：2021-02-19
Applicant: Universiteit Maastricht , Academisch Ziekenhuis Maastricht , Roche Diagnostics Operations, Inc.
Inventor： Alfred Engel , Michael Gerg , Ute Jucknischke , Johann Karl , Peter Kastner , Thomas Meier , Lars Hillringhaus , Ulrich Schotten , Vinzent Rolny , Ursula-Henrike Wienhues-Thelen , André Ziegler , Roberto Latini , Jennifer Marie Theresia Anna Meessen
Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of BMP10 in a sample from the subject, and comparing the amount of BMP10 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure based on the determination of BMP 10 in a sample from a subject. Further, the present invention relates to a method for predicting the risk of a subject of hospitalization due to heart failure based on the determination of a BMP10-type peptide in a sample from a subject. The present invention further pertains to antibodies which bind to one or more BMP10-type peptides such as NT-proBMP10.
-
公开(公告)号：US20200371114A1
公开(公告)日：2020-11-26
申请号：US16721112
申请日：2019-12-19
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Roberto Latini , Serge Masson , Dirk Block , Christian Zaugg , Thomas Dieterle , Edelgard Kaiser , Johann Karl , Vinzent Rolny , Ursula-Henrike Wienhues-Thelen
IPC: G01N33/68
Abstract: The present invention relates to a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from the group consisting of a BNP-type peptide, IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject. The method may further encompass the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy. Further envisaged by the present invention are devices adapted to carry out the present invention.
-
Patent Agency Ranking
公开(公告)号：US10557858B2
公开(公告)日：2020-02-11
申请号：US15581587
申请日：2017-04-28
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Roberto Latini , Serge Masson , Dirk Block , Christian Zaugg , Thomas Dieterle , Edelgard Kaiser , Johann Karl , Vinzent Rolny , Ursula-Henrike Wienhues-Thelen
Abstract: Described is a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from B-type natriuretic peptide (BNP) or N-terminal pro B-type natriuretic peptide (NT-proBNP), IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject along with the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy.
-
7.发明申请公开(公告)号：US20150233946A1
公开(公告)日：2015-08-20
申请号：US14705528
申请日：2015-05-06
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Dirk Block , Roberto Latini , Serge Masson , Ursula-Henrike Wienhues-Thelen , Christian Zaugg , Andre Ziegler
IPC: G01N33/68
CPC classification number: G01N33/6887 , G01N33/6869 , G01N33/6893 , G01N2333/4712 , G01N2333/4737 , G01N2333/4745 , G01N2333/5412 , G01N2333/58 , G01N2800/326 , G01N2800/52
Abstract: The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac Troponin, NT-proBNP (N-terminal prohormone of brain natriuretic peptide), hsCRP, IL-6 (Interleukin-6) and IGFBP7 (Insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). Further, the present invention relates to a method for identifying a subject being treatable with anticoagulation therapy. Further envisaged are systems, reagents and kits used in performing the methods disclosed herein.
Abstract translation: 本发明涉及一种诊断近期阵发性房颤的方法。 该方法基于选自心肌肌钙蛋白，NT-proBNP（脑钠尿肽的N-末端激素原），hsCRP，IL-6（白细胞介素-6）和IGFBP7（ 来自受试者的样品中的胰岛素样生长因子结合蛋白7），以及由此确定的量与参考量（参考量）的比较。 此外，本发明涉及用抗凝治疗来鉴别受治疗者的方法。 进一步设想的是用于执行本文公开的方法的系统，试剂和试剂盒。
-
公开(公告)号：US20230366894A1
公开(公告)日：2023-11-16
申请号：US18028235
申请日：2021-09-30
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Johann Karl , Peter Kastner , Roberto Latini , Serge Masson , Jennifer Marie Theresia Anna Meessen , Vinzent Rolny , Ursula-Henrike Wienhues-Thelen , André Ziegler
IPC: G01N33/74
CPC classification number: G01N33/74 , G01N2333/58 , G01N2440/38 , G01N2800/326
Abstract: The present invention relates to a method for diagnosing atrial fibrillation in a subject, said method comprising the steps of a) determining the amount of total NT-proBNP in sample from the subject, b) determining the amount of unglycosylated NT-proBNP in a sample from the subject, c) calculating a score of the amounts determined in steps a) and b), d) comparing the calculated score with a reference score, and e) diagnosing atrial fibrillation in a subject.
-
公开(公告)号：US20230062697A1
公开(公告)日：2023-03-02
申请号：US17821951
申请日：2022-08-24
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Dirk Block , Roberto Latini , Serge Masson , Ursula-Henrike Wienhues-Thelen , Christian Zaugg , Andre Ziegler
Abstract: The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac Troponin, NT-proBNP (N-terminal prohormone of brain natriuretic peptide), hsCRP, IL-6 (Interleukin-6) and IGFBP7 (Insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). Further, the present invention relates to a method for identifying a subject being treatable with anticoagulation therapy. Further envisaged are systems, reagents and kits used in performing the methods disclosed herein.
-
10.发明申请公开(公告)号：US20190353666A1
公开(公告)日：2019-11-21
申请号：US16217612
申请日：2018-12-12
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Herbert Andres , Dirk Block , Johann Karl , Peter Kastner , Ursula-Henrike Wienhues-Thelen , Roberto Latini , Serge Masson , Andre Ziegler , Edelgard Kaiser , Stefan Palme , Markus Thomas , Simona Barlera
IPC: G01N33/68
Abstract: The present disclosure relates to a method for predicting the risk of recurrence of Atrial Fibrillation in a subject based on determining the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. The present disclosure also contemplates a method of diagnosing Atrial Fibrillation in a subject suspected to suffer from Atrial Fibrillation based on determining the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. Further envisaged are devices adapted to carry out the method of the present disclosure.
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.016 seconds)
